Clinical summary
A Multi-Institutional Phase 2 Trial of High-Dose SAbR for Prostate Cancer Using Rectal Spacer
By: Folkert MC, Zelefsky MJ, Hannan R, et al.
High-dose stereotactic ablative radiotherapy (SAbR) for prostate cancer (PCa) offers the radiobiologic potency of the most intensified radiation therapy regimens, but was associated with >90% rates of ulceration of the anterior rectal wall on endoscopic assessment that infrequently progressed to severe rectal toxicity in prior prospective series. A multi-institutional Phase II prospective trial was conducted to assess whether placement of a peri-rectal hydrogel spacer would reduce acute periprostatic rectal ulcer events following high dose (> 40 Gy) SAbR.